Take­da bags $280M, sells off its stake in a Chi­na drug JV ahead of $62B Shire buy­out

Let the re­struc­tur­ing of Take­da be­gin now.

The Japan­ese phar­ma com­pa­ny is sell­ing off its end of a Chi­nese mar­ket­ing and R&D joint ven­ture for $280 mil­lion. That’s not much cash for Take­da right now, which is tak­ing on a heavy debt load as it push­es ahead with plans to buy Shire for $62 bil­lion. 

But every­thing helps.

Take­da’s rum­mage sale starts with its 51.34% stake in Guang­dong Tech­pool Bio-Phar­ma Co (Tech­pool), which is en­gaged in “the re­search, dis­cov­ery and mar­ket­ing of uri­nary pro­tein bio­phar­ma­ceu­ti­cals and pro­duc­tion of bio­phar­ma­ceu­ti­cals in crit­i­cal care.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER